CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced that they have entered into an exclusive license agreement with Massachusetts General Hospital to access intellectual property and technology related to the CRISPR/Cas9 and TALENs genome editing systems. The license allows broad utilization of the technology developed in the laboratory of Editas founder, J. Keith Joung, M.D., Ph.D., for the prevention and treatment of human or animal disease, and broad agricultural use.
Help employers find you! Check out all the jobs and post your resume.
